Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H16N2O2 |
Molecular Weight | 208.2569 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
InChI
InChIKey=QCHFTSOMWOSFHM-WPRPVWTQSA-N
InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
Molecular Formula | C11H16N2O2 |
Molecular Weight | 208.2569 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | SALAGEN Approved UseSALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date7.642944E11 |
|||
Palliative | SALAGEN Approved UseSALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date7.642944E11 |
|||
Primary | ISOPTO CARPINE Approved UseIsopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date1.27716478E12 |
|||
Primary | ISOPTO CARPINE Approved UseIsopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date1.27716478E12 |
|||
Primary | ISOPTO CARPINE Approved UseIsopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date1.27716478E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15 ng/mL |
5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PILOCARPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33 ng × h/mL |
5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PILOCARPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.76 h |
5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PILOCARPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PILOCARPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: Page: p. 36 |
unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: Page: p. 36 |
Disc. AE: Vision blurred... AEs leading to discontinuation/dose reduction: Vision blurred (moderate, 2 patients) Sources: Page: p. 36 |
20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Other AEs: Increased salivation, Lacrimation... Other AEs: Increased salivation (1 patient) Sources: Lacrimation (1 patient) Vomiting (1 patient) Anxiety (1 patient) Tremor (1 patient) |
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy n = 2 Health Status: unhealthy Population Size: 2 Sources: |
|
1.54 % 3 times / day multiple, topical Recommended Dose: 1.54 %, 3 times / day Route: topical Route: multiple Dose: 1.54 %, 3 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: xerostomia Population Size: 20 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vision blurred | moderate, 2 patients Disc. AE |
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: Page: p. 36 |
unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: Page: p. 36 |
Anxiety | 1 patient | 20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Increased salivation | 1 patient | 20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Lacrimation | 1 patient | 20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Tremor | 1 patient | 20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Vomiting | 1 patient | 20 mg single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
moderate | |||
Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0 |
yes [Ki 1 uM] | |||
yes [Ki 360 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
weak | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0 |
||
yes | ||||
Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0 |
yes | |||
Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0 |
yes | unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Norepinephrine in treatment of ocular hypertension and glaucoma. | 1975 Mar |
|
[The effect of physiological and extreme irritants on zinc metabolism in pancreatic islets and hippocampus cells]. | 2001 |
|
Synchronized feeding as a "conditioned stimulus" for overt seizures in chronically (limbic) epileptic rats: a model for "psychogenic seizures" with complex partial epilepsy. | 2001 |
|
A new medication for treatment of dry mouth in Sjögren's syndrome. | 2001 Apr |
|
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study. | 2001 Apr |
|
2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. | 2001 Apr |
|
Alkaline phosphatase activity in whitefly salivary glands and saliva. | 2001 Apr |
|
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. | 2001 Apr |
|
Stress response to surgical procedures in the submandibular region and its influence on salivary secretion in mice. | 2001 Apr |
|
Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. | 2001 Apr 1 |
|
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. | 2001 Apr 17 |
|
Exploring the potential for subtype-selective muscarinic agonists in glaucoma. | 2001 Apr 27 |
|
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. | 2001 Apr 27 |
|
Alteration of cardiovascular and neuronal function in M1 knockout mice. | 2001 Apr 27 |
|
The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. | 2001 Aug |
|
Beta-adrenergic blocker therapy and the trabecular meshwork. | 2001 Feb |
|
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. | 2001 Feb |
|
Brief successive temporal observational sampling as a possible indicator of daily overt seizure activity in epileptic rats. | 2001 Feb |
|
The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension. | 2001 Feb |
|
Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. | 2001 Feb |
|
Normalization of spatial learning despite brain damage in rats receiving ketamine after seizure-induction: evidence for the neuromatrix. | 2001 Feb |
|
Do recurrent febrile convulsions decrease the threshold for pilocarpine-induced seizures? Effects of nitric oxide. | 2001 Feb 28 |
|
Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. | 2001 Jan |
|
[Dry mouth]. | 2001 Jan 31 |
|
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system. | 2001 Jul |
|
Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats. | 2001 Jul |
|
Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine. | 2001 Jul |
|
Defective fluid secretion and NaCl absorption in the parotid glands of Na+/H+ exchanger-deficient mice. | 2001 Jul 20 |
|
Evaluation of spontaneous contamination of ocular medications. | 2001 Jul-Aug |
|
Activity-induced expression of common reference genes in individual cns neurons. | 2001 Jun |
|
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours. | 2001 Jun |
|
Potential mechanism for the additivity of pilocarpine and latanoprost. | 2001 Jun |
|
Behavioral and electroencephalographic analysis of seizures induced by intrahippocampal injection of granulitoxin, a neurotoxic peptide from the sea anemone Bunodosoma granulifera. | 2001 Jun |
|
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. | 2001 Jun 1 |
|
Modulators with convergent cellular actions elicit distinct circuit outputs. | 2001 Jun 1 |
|
Agonistic behavior in groups of limbic epileptic male rats: pattern of brain damage and moderating effects from normal rats. | 2001 Jun 29 |
|
Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation. | 2001 Jun 29 |
|
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy. | 2001 Jun 8 |
|
Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents. | 2001 Mar |
|
Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil. | 2001 Mar |
|
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model. | 2001 Mar |
|
Lithium does not synergize the peripheral action of cholinomimetics as seen in the central nervous system. | 2001 Mar 23 |
|
In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug. | 2001 Mar-Apr |
|
Amino acid derivatives with anticonvulsant activity. | 2001 May |
|
Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. | 2001 May |
|
Lack of effect of mossy fiber-released zinc on granule cell GABA(A) receptors in the pilocarpine model of epilepsy. | 2001 May |
|
Diurnal variation in pilocarpine-induced generalized tonic-clonic seizure activity. | 2001 May |
|
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland. | 2001 May 1 |
|
Status epilepticus causes necrotic damage in the mediodorsal nucleus of the thalamus in immature rats. | 2001 May 15 |
|
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine. | 2001 May 25 |
Sample Use Guides
Ophthalmic solution: Instill one drop in the eye(s) up to four times daily. Oral formulation: the recommended dose is 5 mg taken three times a day (Head and Neck Cancer Patients) or 5 mg taken four times a day (Sjogren's Syndrome Patients).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25886199
Rat submandibular gland cells were treated wth 100 uM pilocarpine. The drug elicited a small and sustained increase in [Ca2+]i, indicating that pilocarpine acts as a partial agonist for mAChR-mediated Ca2+ responses.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:53:58 UTC 2022
by
admin
on
Fri Dec 16 16:53:58 UTC 2022
|
Record UNII |
01MI4Q9DI3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN07AX01
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-ATC |
N07AX01
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-VATC |
QS01EB01
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
FDA ORPHAN DRUG |
45990
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.4
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NDF-RT |
N0000000104
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NDF-RT |
N0000175884
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-ATC |
S01EB01
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-VATC |
QS01EB51
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
WHO-ATC |
S01EB51
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NDF-RT |
N0000175369
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NDF-RT |
N0000000104
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
||
|
NDF-RT |
N0000000104
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01085
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
8328
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | RxNorm | ||
|
DTXSID1021162
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
3163
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
202-128-4
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
Pilocarpine
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
01MI4Q9DI3
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
CHEMBL550
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
01MI4Q9DI3
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
PILOCARPINE
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
305
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
92-13-7
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
D010862
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
5910
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
SUB03818MIG
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
M8806
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | Merck Index | ||
|
8207
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
2166
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
C62068
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY | |||
|
1538505
Created by
admin on Fri Dec 16 16:53:58 UTC 2022 , Edited by admin on Fri Dec 16 16:53:58 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||